publication date: Sep. 1, 2017
Issue 32 - Sep. 1, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Peter Pisters tapped to lead MD Anderson

    Peter Pisters, a sarcoma and pancreatic cancer surgeon and an MD Anderson expat who serves as president and CEO of University Health Network of Toronto, is set to become the fifth president of the Houston-based cancer center.

    Pisters was chosen by the UT System Board of Regents at a special meeting Aug. 25.

  • NCI requests $591 million in additional funding for FY19

    NCI is asking for $6.38 billion for fiscal year 2019­—nearly $1 billion, or 12 percent, above FY17 appropriation levels—to fully fund promising research areas.

    The institute’s FY19 professional judgment budget proposal, also known as the Bypass Budget, is a unique authority established by the National Cancer Act of 1971.

  • In Brief

    • Guenther Koehne named chief of bone marrow transplantation and hematologic oncology at Miami Cancer Institute
    • Prostate Cancer Foundation awards $6 Million in 2017 Challenge Awards
    • Rick Kittles joins City of Hope as director of the Division of Health Equities
    • William Dale joins City of Hope as professor of supportive care
    • Deric Savior promoted to head of medical oncology at Temple University Hospital
    • Carlyn Tan joins department of hematology/oncology at Fox Chase 
    • Reza Nejati joins pathology department at Fox Chase
    • CPRIT awards $102 million in 60 new grants 
  • Drugs and Targets

    • Novartis’s Kymriah becomes first gene therapy to get FDA approval
    • FDA approves Mylotarg for treatment of acute myeloid leukemia
    • FDA approves Lynparza (olaparib) tablets for maintenance treatment in ovarian cancer
    • FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL
    • Ocugen gets Orphan Drug designation for ocular graft vs. host disease
    • Gazyva in previously untreated follicular lymphoma gets FDA priority review 
    • EU approves AVEO’s Fotivda (tivozanib) for advanced renal cell carcinoma
    • FDA acts to remove unproven treatment used in ‘stem cell’ centers

Copyright (c) 2017 The Cancer Letter Inc.